Follows adults with psoriatic arthritis treated with risankizumab over time
Observes how long adults with psoriatic arthritis stay on risankizumab compared with other treatments.
Plain-language title generated from the registry record
Registry title: An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
Key facts
- Where
- Granada, Huelva, Lorca, Madrid, Málaga, Murcia, Seville, and Vigo, SpainSee the 11 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06764693, who can take part
Where in Spain
- Hospital Universitario Clinico San Cecilio /ID# 272665Granada, SpainTaking people
- Hospital Universitario Virgen de las Nieves /ID# 275741Granada, SpainTaking people
- Hospital Juan Ramón Jiménez /ID# 272667Huelva, SpainTaking people
- Hospital Rafael Mendez /ID# 272663Lorca, SpainTaking people
- Hospital Universitario 12 de Octubre /ID# 272660Madrid, SpainTaking people
- Hospital Universitario de La Princesa /ID# 264073Madrid, SpainTaking people
- Hospital Universitario La Paz /ID# 264316Madrid, SpainTaking people
- Hospital Universitario Virgen de la Victoria /ID# 264317Málaga, SpainTaking people
- Hospital General Universitario Reina Sofía /ID# 272664Murcia, SpainTaking people
- Hospital Universitario de Valme /ID# 264314Seville, SpainTaking people
- Hospital Xeral Cies (CHUVI) /ID# 272659Vigo, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AbbVie
- Trial code
- NCT06764693
- Record updated
- 17 February 2026
- Original description
Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. This study aims to describe the long term usage and effectiveness with risankizumab (RZB) relative to other advanced therapeutic options for the management of PsA in daily clinical practice.Read full original descriptionShow less
Prospective Multi-country, Real-world, Multi-arm Study of Treatment PErsistence With RISankizumab in Psoriatic Arthritis (PERIS)
Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. This study aims to describe the long term usage and effectiveness with risankizumab (RZB) relative to other advanced therapeutic options for the management of PsA in daily clinical practice.
Risankizumab is an approved drug for the treatment of psoriatic arthritis. The study will not be conducted in the United States, however it will be conducted in approximately 15 countries and include at least 900 and up to 1200 participants with a 2 to1 ratio of participant allocation between participants receiving risankizumab and participants receiving other advanced therapeutic agents.
The therapy is prescribed in the usual manner in accordance with the terms of the local marketing authorization and professional and reimbursement guidelines with regards to dose, population, and indication. All study visits will occur during routine clinical practice and participants will be followed for 24 months.
There is expected to be no additional burden for participants in this study.
Inclusion: Participant with a clinical diagnosis of psoriatic arthritis (PsA) with symptom onset at least 6 months prior to the Screening visit and fulfillment of ClASsification for Psoriatic ARthritis (CASPAR) at Baseline visit to confirm that the participant has active disease; Participant must have demonstrated an inadequate response to at least 1 Disease-modifying antirheumatic drug (DMARD) (with max 50% Biologic DMARD-Inadequate Response); alternatively, participant must have demonstrated an intolerance to or contraindication for csDMARDs as determined by the investigator.
Exclusion: Participants demonstrated an inadequate response to three or more bDMARDs/targeted synthetic DMARDs (tsDMARDs).